Protocol Ledger

NCT05794906 · Phase III · ACTIVE NOT RECRUITING

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Thera

Interventional Phase III clinical trial protocol NCT05794906 sponsored by Bayer in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2023-04-03 Enrollment: 985 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05794906
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)985 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05794906
Protocol FieldVerified Registry Value
NCT IdentifierNCT05794906
Consolidated Lead SponsorBayer
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment985 participants (ACTUAL)
Registered Start Date2023-04-03
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bayer across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI